Our findings suggest that CD276 may serve as animportant target for future ccRCC therapy, and downregulation of CD276 expressionlevels may help overcome sunitinib resistance in patients with ccRCC. The gene discussed is CD276; the disease is nonpapillary renal cell carcinoma.